Case Report - Archives of Medical Case Reports (2021) Volume 3, Issue 2
Introduction: Imatinib therapy for gastrointestinal stromal tumors (GIST) rarely can cause pigmentary changes. When associated with sensitive areas such as the face, it can cause significant psychosocial impact and efforts should be made to correct it. Here we describe a case of hypopigmentation affecting the face in an African American female with concurrent development of neutropenia with resolution upon dose reduction of imatinib.
Imatinib, Tyrosine kinase inhibitor (TKI), Hypopigmentation, Hyperpigmentation, CML, GIST, Rash, Cutaneous adverse effect, Neutropenia